BMY Bristol Myers Squibb Co

  1. Stocks
  2. Healthcare
  3. NYSE: BMY

Price (delayed)

$49.88

Market cap

$101.49B

P/E Ratio

12.56

Dividend/share

$2.28

EPS

$3.97

Enterprise value

$131.58B

Bristol Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, ...

Highlights
The stock's price to earnings (P/E) is 34% less than its last 4 quarters average of 19.0
Bristol Myers Squibb's EPS has increased by 28% YoY and by 5% QoQ
The quick ratio has decreased by 21% YoY and by 18% QoQ
Bristol Myers Squibb's equity has decreased by 11% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.bms.com/
Peers: MRK LLY PFE JNJ

Key stats

What are the main financial stats of BMY
Market
Shares outstanding
2.03B
Market cap
$101.49B
Enterprise value
$131.58B
Valuations
Price to earnings (P/E)
12.56
Price to book (P/B)
3.59
Price to sales (P/S)
2.32
EV/EBIT
15.29
EV/EBITDA
7.14
EV/Sales
2.93
Earnings
Revenue
$44.94B
EBIT
$8.61B
EBITDA
$18.42B
Free cash flow
$11.69B
Per share
EPS
$3.97
Free cash flow per share
$5.6
Book value per share
$13.88
Revenue per share
$21.51
TBVPS
$19.71
Balance sheet
Total assets
$91.26B
Total liabilities
$62.2B
Debt
$37.6B
Equity
$29B
Working capital
$4.17B
Liquidity
Debt to equity
1.3
Current ratio
1.18
Quick ratio
0.77
Net debt/EBITDA
1.63
Margins
EBITDA margin
41%
Gross margin
76.5%
Net margin
18.4%
Operating margin
19.2%
Efficiency
Return on assets
8.8%
Return on equity
26.8%
Return on invested capital
17.6%
Return on capital employed
12.7%
Return on sales
19.2%
Dividend
Dividend yield
4.57%
DPS
$2.28
Payout ratio
57.4%

BMY stock price

How has the Bristol Myers Squibb stock price performed over time
Intraday
-0.7%
1 week
2.38%
1 month
-5.51%
1 year
-37.59%
YTD
-30.67%
QTD
-14.06%

Financial performance

How have Bristol Myers Squibb's revenue and profit performed over time
Revenue
$44.94B
Gross profit
$34.39B
Operating income
$8.63B
Net income
$8.29B
Gross margin
76.5%
Net margin
18.4%
BMY's net margin is up by 29% year-on-year and by 4.5% since the previous quarter
The net income has grown by 24% year-on-year and by 4% since the previous quarter
The operating margin has increased by 16% year-on-year
The operating income rose by 12% year-on-year

Growth

What is Bristol Myers Squibb's growth rate over time

Valuation

What is Bristol Myers Squibb stock price valuation
BMY P/E details
P/E
12.56
P/B
3.59
P/S
2.32
EV/EBIT
15.29
EV/EBITDA
7.14
EV/Sales
2.93
The stock's price to earnings (P/E) is 34% less than its last 4 quarters average of 19.0
Bristol Myers Squibb's EPS has increased by 28% YoY and by 5% QoQ
BMY's P/B is 20% below its last 4 quarters average of 4.5 and 12% below its 5-year quarterly average of 4.1
Bristol Myers Squibb's equity has decreased by 11% YoY and by 9% from the previous quarter
The price to sales (P/S) is 32% less than the 5-year quarterly average of 3.4 and 23% less than the last 4 quarters average of 3.0
The company's revenue fell by 3.9% YoY

Efficiency

How efficient is Bristol Myers Squibb business performance
Bristol Myers Squibb's ROA has increased by 35% YoY and by 6% from the previous quarter
The ROE has grown by 33% YoY and by 7% from the previous quarter
BMY's return on invested capital is up by 21% year-on-year
Bristol Myers Squibb's return on sales has increased by 16% YoY

Dividends

What is BMY's dividend history
Dividend details
DPS
$2.28
Dividend yield
4.57%
Payout ratio
57.4%
Recent dividends

Financial health

How did Bristol Myers Squibb financials performed over time
BMY's total assets is 47% greater than its total liabilities
The quick ratio has decreased by 21% YoY and by 18% QoQ
Bristol Myers Squibb's current ratio has decreased by 17% YoY and by 15% from the previous quarter
BMY's debt is 30% greater than its equity
Bristol Myers Squibb's equity has decreased by 11% YoY and by 9% from the previous quarter
The company's debt to equity rose by 10% QoQ and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.